Twinstrand Therapeutics' Unattributed Round

Twinstrand Therapeutics raised a round of funding on July 13, 1998. Investors include GrowthWorks.

Twinstrand has established a technology that uses modified versions of ricin, a plant-derived cell toxin, as therapeutic prodrugs. Its lead drug, a product known as TST10088, is currently undergoing a…

Articles about Twinstrand Therapeutics' Unattributed Round: